Dominic N. Farsi

Dominic N. Farsi

Auto-generated profile, based on publicly available information

Dominic N. Farsi

Department of Nutritional Sciences, King’s College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in British Journal of Nutrition
Verified
Journal Article
Open access
DFDominic N. Farsi
Dominic N. Farsi
DUDinithi Uthumange
Dinithi Uthumange
Jose MunozJose Munoz
Jose Munoz
DCdaniel commane
daniel commane
Dietary patterns high in meat compromise both planetary and human health. Meat alternatives may help to facilitate meat reduction; however, the nutritional implications of displacing meat with meat alternatives does not appear to have been evaluated. Here, the ninth cycle of the National Diet and Nutrition Survey was used as the basis of models to assess the effect of meat substitution on nutritional intake. We implemented three models; model 1 replaced 25 %, 50 %, 75 % or 100 % of the current meat intake with a weighted mean of meat alternatives within the UK market. Model 2 compared different ingredient categories of meat alternative; vegetable, mycoprotein, a combination of bean and pea, tofu, nut and soya. Model 3 compared fortified v. unfortified meat alternatives. The models elicited significant shifts in nutrients. Overall, carbohydrate, fibre, sugars and Na increased, whereas reductions were found for protein, total and saturated fat, Fe and B12. Greatest effects were seen for vegetable-based (+24·63g/d carbohydrates), mycoprotein-based (–6·12g/d total fat), nut-based (–19·79g/d protein, +10·23g/d fibre; −4·80g/d saturated fat, +7·44g/d sugars), soya-based (+495·98mg/d Na) and tofu-based (+7·63mg/d Fe, −2·02μg/d B12). Our results suggest that meat alternatives can be a healthful replacement for meat if chosen correctly. Consumers should choose meat alternatives low in Na and sugar, high in fibre, protein and with high micronutrient density, to avoid compromising nutritional intake if reducing meat intake. Manufacturers and policy makers should consider fortification of meat alternatives with nutrients such as Fe and B12 and focus on reducing Na and sugar content.

18 January 2023 in European Journal of Nutrition
Verified
Journal Article
Open access
PDF file
DFDominic N. Farsi
Dominic N. Farsi
JGJose Lara Gallegos
Jose Lara Gallegos
GKGeorgios Koutsidis
Georgios Koutsidis
ANAndrew Nelson
Andrew Nelson
TFTim J. A. Finnigan
Tim J. A. Finnigan
DCDaniel M. Commane
Daniel M. Commane
Purpose: The high-meat, low-fibre Western diet is strongly associated with colorectal cancer risk. Mycoprotein, produced from Fusarium venanatum, has been sold as a high-fibre alternative to meat for decades. Hitherto, the effects of mycoprotein in the human bowel have not been well considered. Here, we explored the effects of replacing a high red and processed meat intake with mycoprotein on markers of intestinal genotoxicity and gut health. Methods: Mycomeat (clinicaltrials.gov NCT03944421) was an investigator-blind, randomised, crossover dietary intervention trial. Twenty healthy male adults were randomised to consume 240 g day−1 red and processed meat for 2 weeks, with crossover to 2 weeks 240 g day−1 mycoprotein, separated by a 4-week washout period. Primary end points were faecal genotoxicity and genotoxins, while secondary end points comprised changes in gut microbiome composition and activity. Results: The meat diet increased faecal genotoxicity and nitroso compound excretion, whereas the weight-matched consumption of mycoprotein decreased faecal genotoxicity and nitroso compounds. In addition, meat intake increased the abundance of Oscillobacter and Alistipes, whereas mycoprotein consumption increased Lactobacilli, Roseburia and Akkermansia, as well as the excretion of short chain fatty acids. Conclusion: Replacing red and processed meat with the Fusarium-based meat alternative, mycoprotein, significantly reduces faecal genotoxicity and genotoxin excretion and increases the abundance of microbial genera with putative health benefits in the gut. This work demonstrates that mycoprotein may be a beneficial alternative to meat within the context of gut health and colorectal cancer prevention.

25 August 2023 in European Journal of Nutrition
Verified
Journal Article
Open access
PDF file
DFDominic N. Farsi
Dominic N. Farsi
JGJose Lara Gallegos
Jose Lara Gallegos
TFTim J. A. Finnigan
Tim J. A. Finnigan
WCWilliam Cheung
William Cheung
JMJose Munoz Munoz
Jose Munoz Munoz
DCDaniel M. Commane
Daniel M. Commane
Purpose: Mycoprotein is a relatively novel food source produced from the biomass of Fusarium venenatum. It has previously been shown to improve CVD risk markers in intervention trials when it is compared against total meat. It has not hitherto been assessed specifically for benefits relative to red and processed meat. Methods: We leveraged samples from Mycomeat, an investigator-blind randomised crossover controlled trial in metabolically healthy male adults (n = 20), randomised to consume 240 g/day of red and processed meat for 14 days followed by mycoprotein, or vice versa. Blood biochemical indices were a priori defined secondary endpoints. Results: Mycoprotein consumption led to a 6.74% reduction in total cholesterol (P = 0.02) and 12.3% reduction in LDL cholesterol (P = 0.02) from baseline values. Change in fasted triglycerides was not significantly different between diets (+ 0.19 ± 0.11 mmol/l with mycoprotein, P = 0.09). There was a small but significant reduction in waist circumference for mycoprotein relative to meat (− 0.95 ± 0.42 cm, P = 0.04). Following the mycoprotein diet, mean systolic (− 2.41 ± 1.89 mmHg, P = 0.23) and diastolic blood pressure (− 0.80 ± 1.23 mmHg, P = 0.43) were reduced from baseline. There were no statistically significant effects of the intervention on urinary sodium, nitrite or TMAO; while urinary potassium (+ 126.12 ± 50.30 mmol/l, P = 0.02) and nitrate (+ 2.12 ± 0.90 mmol/l, P = 0.04) were both significantly higher with mycoprotein relative to meat. The study population comprised metabolically healthy adults, therefore, changes in plasma lipids had little effect on cardiovascular risk scores (− 0.34% FRS for mycoprotein P = 0.24). Conclusions: These results confirm potential cardiovascular benefits when displacing red and processed meat with mycoprotein in the diet. Longer trials in higher risk study populations are needed to fully elucidate suggested benefits for blood pressure and body composition. ClinicalTrials.gov Identifier: NCT03944421.

25 September 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
DFDominic N. Farsi
Dominic N. Farsi
PCPaul Cotter
Paul Cotter
Orla O'sullivanOrla O'sullivan
Orla O'sullivan
Skeletal muscle has a profound influence on metabolic health, functional capacity and resilience across the lifespan. Beyond dietary protein and physical activity, the gut microbiome may have the capacity to impact skeletal muscle mass and function through the bidirectional network termed the gut-muscle axis (GMA). Fermented protein foods (FPFs) are protein rich matrices transformed by microbial activity that integrate modified protein structures, bioactive peptides, and live microorganisms, or components thereof, which could modulate skeletal muscle physiology. Here, we review mechanistic, preclinical and human evidence concerning the potential of FPFs to influence skeletal muscle health through GMA modulation. Although emerging human studies suggest favourable effects on metabolic regulation, inflammatory pathways and gut microbial ecology, direct evidence that FPFs impact muscle protein synthesis, muscle mass or function remains limited. Furthermore, the literature is characterised by considerable heterogeneity in interventions and outcome measures. Studies integrating comprehensive microbiome characterisation, multi-omics approaches and direct skeletal muscle phenotyping are needed to determine whether FPFs confer advantages over conventional protein foods or more established microbiome targeted strategies such as probiotic supplementation. Such studies will be essential to elucidate their role in targeted nutritional strategies for ageing, metabolic disease, muscle atrophy, and physical performance.

17 March 2026 in American Journal of Gastroenterology
Verified
Journal Article
Open access
DFDominic N Farsi
Dominic N Farsi
ACAurélie Cotillard
Aurélie Cotillard
BWBridgette Wilson
Bridgette Wilson
DSDaniel So
Daniel So
PGPhilippa S Gibson
Philippa S Gibson
KWKevin Whelan
Kevin Whelan
Background: Specific foods are associated with abdominal bloating, which can significantly impact quality of life. Objective: To identify responders to fiber-induced bloating and the mechanisms underpinning clinical and microbial responses. Design: Double-blind, placebo-controlled, randomized, 2-period, 2-challenge crossover trial in 41 individuals with functional bloating. Participants were randomized to 8 g/d of fructan or α-galacto-oligosaccharides (α-GOS) for 7 days with a 21-day washout. Clinical, nutritional, microbial (shotgun sequencing, metatranscriptomics) and fermentation (short-chain fatty acids, volatile organic compounds, breath hydrogen) profiles were characterized prior to each challenge to identify factors predicting response, and after the challenge to elucidate mechanisms underpinning food-induced bloating. Results: Thirty-nine participants completed both challenges (39 fructan, 40 α-GOS). Overall, seven (7/39, 17.9%) participants were fructan responders and eight (8/40, 20%) were α-GOS responders (experienced fiber-related symptom induction). Clinical metrics indicative of bloating distinguished responders and non-responders to both challenges, including greater abdominal girth (fructan, p = 0.009; α-GOS, p = 0.030). α-GOS responders had higher breath hydrogen (H 2 ) pre-challenge than α-GOS non-responders (p = 0.011). Trends were identified within metagenomic and metatranscriptomic gut microbial analyses, with higher carbohydrate active enzyme (CAZyme) diversity in fructan responders (pre-challenge, adjusted p-value (padj) = 0.024; post-challenge, padj = 0.042), and greater increase in gene expression for gamma-aminobutyric acid (GABA) degradation in α-GOS responders (padj = 0.041). Conclusion: A higher burden of GI symptoms predicts clinical response to fermentable fibers in functional bloating, while for α-GOS, higher repeated fasting breath H 2 is also a predictor. Gut microbiome function and fermentation is associated with functional bloating; however, further investigations are required to draw firm conclusions for the microbial influence in this interplay. ClinicalTrials.gov (Identifier: NCT04802798).

3 September 2019 in Proceedings of the Nutrition Society
Verified
Journal Article
Open access
PDF file
HCHo Ming Cheng
Ho Ming Cheng
DFD. Farsi
D. Farsi
JGJose Lara Gallegos
Jose Lara Gallegos
Traditionally, flow mediated dilation (FMD) has been the method of choice when evaluating endothelial function (1). However, assessments of microvascular vasodilation and arterial stiffness are non-invasive methods increasingly used during the past two decades. Both techniques are increasingly being adopted as clinical measures of vascular function. However, the evidence of the impact of dietary and nutritional interventions on these methods has not been systematically reviewed nor meta-analysed. Here, a systematic review and meta-analysis will be reported on the current literature surrounding effects of on nutritional interventions vascular function assessed by pulse wave velocity (PWV), pulse wave analysis (PWA) and laser doppler imaging (LDI). Three major databases including Medline, Scopus and Web of science were thoroughly searched from inception till January 2019. Intervention trials in adults (≥ than 18 years), reporting on the effect on markers of vascular function including microvascular vasodilation and arterial stiffness were identified. Microvascular vasodilation assessed with the use of Laser Doppler Imaging (LDI), which measured the response to cutaneous perfusion of the forearm with acetylcholine and SNP. Meta-analysis was undertaken using review manager software (REVMAN). Random effects models were used to pool data from studies. Effect size was reported as standardised mean differences (SMD) with 95% confidence intervals. Heterogeneity levels were assessed by the I 2 test, with values over 50% representing significant heterogeneity. Out of 1914 publications identified, 74 fulfilled inclusion criteria. 63 studies were meta-analysed the effect of intervention trials on arterial stiffness. This systematic review and meta-analysis revealed that nutrition intervention significantly improved arterial stiffness, measured by pulse wave analysis (PWA) by SMD 0.17 (95% CI-0.25 to-0.09, p < 0.001) and pulse wave velocity (PWV) by SMD 0.15 (95% CI-0.23 to-0.07, p < 0.001), among adult subjects >18 years of age. The heterogeneity levels were low at 8% for PWA and 0% for PWV. In relation to microvascular vasodilation, seven studies were identified. Meta-analysis was not carried out. Only two studies showed significant improvement in endothelium independent microcirculation vasodilation and one study reported a significant improvement in endothelium dependent microcirculation vasodilation. However, the other five studies, using polyphenol supplementation, did not observe any significant improvement on these outcomes. In conclusion, this review found that nutritional interventions could improve PWV and PWA; however, the magnitude of these results might be of little clinical relevance. This systematic review also revealed that currently, a limited number of studies using LDI show signs of improvement from nutritional intervention. More research is necessary to evaluate and identify interventions that are effective in improving outcomes of microvascular vasodilation and arterial stiffness.